Literature DB >> 9707309

Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia.

C Cabellos1, J Ariza, B Barreiro, F Tubau, J Liñares, R Pallarés, F Manresa, F Gudiol.   

Abstract

The aim of this study was to determine whether procaine penicillin could be used in the treatment of suspected pneumococcal pneumonia of mild to moderate severity in an area with a high prevalence of penicillin resistance. Forty-nine patients were treated with 1.2 x 10(6) U of i.m. procaine penicillin every 12 h. By intent-to-treat analysis, 40 of 49 patients were cured and no patient died. Streptococcus pneumoniae could be demonstrated in 17 patients; 5 of 17 isolates were resistant to penicillin (MICs 0.25-4 microg/ml). Fifteen of 17 patients were cured with procaine penicillin, one presented allergy, and one was a therapeutic failure. Mean penicillin serum levels were 2.39 +/- 1.16 microg/ml (peak) and 0.61 +/- 0.38 microg/ml (trough). The results suggest that procaine penicillin may still be useful in the empirical therapy of suspected pneumococcal pneumonia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707309     DOI: 10.1007/bf01699983

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989.

Authors:  A Fenoll; C Martín Bourgon; R Muñóz; D Vicioso; J Casal
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

2.  Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci.

Authors:  P F Viladrich; F Gudiol; J Liñares; G Rufi; J Ariza; R Pallares
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

3.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 4.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

5.  Comparative susceptibilities of penicillin-resistant pneumococci to co-trimoxazole, vancomycin, rifampicin and fourteen beta-lactam antibiotics.

Authors:  J Liñares; J L Perez; J Garau; L Murgui; R Martín
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

Review 6.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

7.  Multiple changes of penicillin-binding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  R Hakenbeck; M Tarpay; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Efficacy, safety, and therapeutic relevance of transthoracic aspiration with ultrathin needle in nonventilated nosocomial pneumonia.

Authors:  J Dorca; F Manresa; L Esteban; B Barreiro; E Prats; J Ariza; R Verdaguer; F Gudiol
Journal:  Am J Respir Crit Care Med       Date:  1995-05       Impact factor: 21.405

9.  Streptococcus pneumoniae resistant to penicillin and chloramphenicol.

Authors:  P C Appelbaum; A Bhamjee; J N Scragg; A F Hallett; A J Bowen; R C Cooper
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

10.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

Authors:  R Pallares; J Liñares; M Vadillo; C Cabellos; F Manresa; P F Viladrich; R Martin; F Gudiol
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

View more
  1 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.